New insider activity at Cassava Sciences ( (SAVA) ) has taken place on September 23, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
President & CEO Richard Barry has made a significant investment in Cassava Sciences by purchasing 7,172 shares of the company’s stock, amounting to a total value of $16,352.
Recent Updates on SAVA stock
Cassava Sciences has recently released a corporate presentation as part of a Form 8-K filing, which is available in the ‘Investors’ section of its website. Despite this update, the stock has been rated as a Hold with a $2.00 price target by analysts. The company’s financial challenges are highlighted by its lack of revenue and ongoing operational losses, contributing to a low financial performance score. Technical indicators suggest bearish trends, and the negative P/E ratio raises valuation concerns. However, a strategic license agreement with Yale University could potentially offer future growth opportunities, although it is currently considered speculative. The overall sentiment remains neutral due to these factors.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
YTD Price Performance: -15.64%
Average Trading Volume: 1,042,780
Technical Sentiment Signal: Sell
Current Market Cap: $112.1M